The objective of SCIENTEX is to allow its clients to enjoy its experience from science to stock exchange, in order to serve them, the most effectively possible at corporate level.After a first R&D experience on radiopharmaceuticals at AREVA / CEA in 1993, Tim Muller worked as a pre-clinical pharmacochemist for the pharmaceutical industry (SERVIER) during 5 years on diabete mellitus & CNS up to proof of concept. Then Tim moved in 1999 to the private equity industry (CDC enterprises & Sofimac Partners) investing in 17 healthcare private companies (7 were acquired by industrials & 4 IPOs). Tim was an active non executive board member on 22 healthcare companies in Europe. Tim created then SCIENTEX in 2006 in order to act as a day to day transition manager in business & corporate development, and M&A (buy side & sell side) for small and medium healthcare companies, while he was advising in parallel wealthy individuals on VIX trading & working with secondary private equity funds. After +26 corporate development missions through Scientex in 6 years, Tim joined CROSSJECT in 2012 (see profile) during its restart in order to drive the new business & corporate development. Then, after the succesfull completion of a 472M$ licensing deal; Tim, in its position of member of the executive board, lead the $6M refinancing closed in june 2013, manage M&A opportunities & engage the IPO process, successfully oversubscribed 4,4 x in february 2014 (Photo1 & Photo2). Globally, Tim has been involved in + 95 corporate and business transactions, including 5 IPOs and 9 M&A. Berenice Muller, associate founding partner, PharmD (2001) & Master degree in Medtech, is developing Scientex offer's in business development towards European SME in order to cover deeply the French market, while Tim focuses on international operations.